CARSON CITY, Nev., Sept. 30, 2026 (GLOBE NEWSWIRE) — American Lithium Minerals, Inc. (OTC: AMLM) today announced that it has successfully completed its PCAOB-standard financial audit, marking a major milestone in the Company’s capital-markets strategy. With audited financials now finalized, AMLM confirms its intention to uplist to the OTCQB Venture Market in the fourth quarter of 2026.

Audit Completion and OTCQB Eligibility

The Company’s completion of a full PCAOB audit satisfies one of the core eligibility requirements for OTCQB, including:

  • Audited annual financial statements prepared in accordance with U.S. GAAP
  • Current SEC-equivalent reporting compliance
  • Minimum bid price and corporate governance standards

This achievement positions AMLM to transition from the OTC market to OTCQB, a tier recognized for higher reporting transparency and investor-focused disclosure.

Strategic Advantages of Uplisting to OTCQB

Uplisting to OTCQB is expected to provide AMLM with several material benefits:

  • Enhanced Credibility — OTCQB issuers must meet stringent financial reporting and governance standards, improving institutional and investor confidence.
  • Greater Market Visibility — OTCQB companies receive expanded market data distribution, including real-time quotes through major financial platforms.
  • Improved Liquidity — The OTCQB tier historically supports higher trading liquidity due to increased investor access and transparency.
  • Broader Investor Base — Many U.S. and international brokers permit trading of OTCQB securities but restrict OTC securities.
  • Strengthened Capital-Markets Positioning — OTCQB status supports future financing initiatives, strategic partnerships, and potential uplisting to senior exchanges.

Management Commentary

President Frank Kristan stated: “Completing our PCAOB audit is a foundational step in strengthening the company’s financial reporting and governance. Uplisting to OTCQB in the fourth quarter will significantly expand our visibility, credibility, and access to capital as we advance our critical-minerals portfolio.”

About American Lithium Minerals, Inc.

American Lithium Minerals, Inc. (OTC: AMLM) is a multi-commodity critical minerals exploration company headquartered in Carson City, Nevada. The Company holds active project interests in gold, silver, copper, lithium, and rare earth elements across Nevada (USA), Chile, British Columbia, Yukon and Quebec (Canada), and Western Australia. AMLM’s portfolio includes 11 active project interests, including the Higginsville gold project in Western Australia, silver and copper exploration in Chile, rare earth interests in Quebec, and lithium properties in Nevada.(www.americanmineralresources.com)

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance or results. Such statements involve a number of risks and uncertainties, including, without limitation, statements regarding the Company’s strategic initiatives, project development plans, expected commodity exposure, anticipated market conditions, the strength of macro tailwinds across critical minerals sectors, and the Company’s ability to advance its multi-commodity portfolio.

Investor Contact

American Lithium Minerals, Inc.
1007 South Street
Carson City, Nevada 89701
Telephone: (775) 587-6137
Email: info@americanmineralresources.com
Website: www.americanmineralresources.com
X / Twitter: American Mineral Resources (OTCID:AMLM) (@AMR_MineralRes) / X
LinkedIn: linkedin.com/company/american-mineral-resources

REVTORPYK (gedatolisib)

REVTORPYK (gedatolisib) vial and box
REVTORPYK (gedatolisib) vial and box
  • REVTORPYK is indicated for patients with HR+/HER2- advanced breast cancer without a PIK3CA mutation detected following progression on or after at least one line of endocrine therapy in the metastatic setting
  • REVTORPYK is the first and only FDA-approved therapy that inhibits all class I PI3K isoforms (α, β, δ, γ) and mTOR complexes mTORC1 and mTORC2 to comprehensively blockade the PI3K/AKT/mTOR (“PAM”) pathway
  • In the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial, the REVTORPYK triplet and REVTORPYK doublet reduced the risk of disease progression or death by 76% and 67%, respectively, compared to fulvestrant
  • Healthcare providers can visit www.revtorpykhcp.com to access a comprehensive patient support program through REVTORPYK Support Services

MINNEAPOLIS, Sept. 30, 2026 (GLOBE NEWSWIRE) — Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that REVTORPYK™ (gedatolisib) is now commercially available in the United States for eligible patients with hormone receptor-positive (“HR+”), human epidermal growth factor receptor 2-negative (“HER2-”), locally advanced or metastatic breast cancer (“ABC”) without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting. REVTORPYK was approved in combination with palbociclib and fulvestrant (“REVTORPYK triplet”) and in combination with fulvestrant (“REVTORPYK doublet”), by the U.S. Food and Drug Administration (“FDA”) on July 14, 2026.

“Our experienced commercial and medical affairs teams have been laying the groundwork for a successful launch with healthcare providers, payers, and patient advocacy partners since REVTORPYK was approved,” said Brian Sullivan, CEO and co-founder of Celcuity. “Now that REVTORPYK is commercially available, we are focused on working with physicians to bring this new treatment option to patients living with HR+/HER2- advanced breast cancer.”

As part of its commitment to patient access, Celcuity has launched the REVTORPYK Support Services program to provide financial assistance and treatment enrollment resources for physicians and eligible patients. The program offers support with insurance coverage, including access and reimbursement, and facilitates access to financial assistance, including Copay Assistance and Patient Assistance Programs. For more information, healthcare providers can visit www.revtorpykhcp.com or contact REVTORPYK Support Services at 877-4-CELCUITY (877-423-5284).

“There is an urgent need for new and differentiated treatment options for patients with HR+/HER2-, PIK3CA wild-type advanced breast cancer in the second-line setting,” said Igor Gorbatchevsky, MD, Chief Medical Officer of Celcuity. “REVTORPYK demonstrated unprecedented clinical benefit in the pivotal VIKTORIA-1 study, and we believe, provides an important new therapeutic option to address this need. We are excited now to make this new therapy available to physicians and their patients.”

Celcuity submitted a supplemental New Drug Application to the FDA in August for REVTORPYK to treat patients with HR+/HER2-, PIK3CA mutated, advanced breast cancer based on the results of Study 2 of the VIKTORIA-1 trial. If approved, physicians would have the option to prescribe REVTORPYK for patients with advanced breast cancer regardless of their PIK3CA tumor status.

About HR+/HER2- Breast Cancer
Breast cancer is the second most common cancer and one of the leading causes of cancer-related deaths worldwide.1 More than two million breast cancer cases were diagnosed globally in 2022.1 While survival rates are high for those diagnosed with early breast cancer, only approximately 30% of patients who are diagnosed with or who progress to metastatic disease are expected to live five years after their diagnosis.2 HR+/HER2- breast cancer is the most common subtype of breast cancer, accounting for approximately 70% of all breast cancers.2

About REVTORPYK (gedatolisib)
REVTORPYK is a kinase inhibitor of class I PI3K isoforms (α, β, δ, γ) and mTOR complexes mTORC1 and mTORC2, resulting in downstream inhibition of multiple effectors, including AKT.3,4,5

REVTORPYK is in development for the first-line treatment of HR+/HER2- ABC and for the second-line treatment of metastatic castration-resistant prostate cancer.

Indication Statement
REVTORPYK (gedatolisib) is a kinase inhibitor indicated in combination with fulvestrant, with or without palbociclib, for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Stomatitis: REVTORPYK can cause severe stomatitis, including ulcers and oral mucositis. Stomatitis occurred in 72% of patients treated with REVTORPYK with fulvestrant and palbociclib, including Grade 3 events in 22% of patients. Stomatitis occurred in 58% of patients treated with REVTORPYK with fulvestrant, including Grade 3 events in 12% of patients. Initiate a steroid-containing, alcohol-free mouthwash prior to starting treatment with REVTORPYK and continue prophylactically during treatment. Monitor patients for signs and symptoms of stomatitis. Withhold, reduce dose, or permanently discontinue REVTORPYK based on severity.

Dermatologic Adverse Reactions: REVTORPYK can cause severe rash. Rash occurred in 30% of patients treated with REVTORPYK in combination with fulvestrant and palbociclib, including Grade 3 events in 6% of patients. Rash occurred in 40% of patients treated with REVTORPYK with fulvestrant, including 5% of patients with Grade 3 events. Monitor patients for rash and infectious sequelae. Instruct patients to limit sun exposure during REVTORPYK treatment. Withhold, reduce dose, or permanently discontinue REVTORPYK based on severity.

Hyperglycemia: REVTORPYK can cause severe hyperglycemia. Monitor fasting glucose prior to initiating treatment with REVTORPYK and periodically during treatment. Monitor HbA1c level if clinically indicated. Increased fasting glucose occurred in 46% of patients receiving REVTORPYK in combination with fulvestrant and palbociclib (Grade 3: 0.9%) and in 57% of patients receiving REVTORPYK in combination with fulvestrant (Grade 3: 1.8%). The safety of REVTORPYK has not been established in patients with Type 1 or uncontrolled Type 2 diabetes mellitus. Patients with well-controlled Type 2 diabetes may require intensified antihyperglycemic therapy and close monitoring of fasting glucose. Manage hyperglycemia with antihyperglycemic medications as clinically indicated. Evaluate fasting blood glucose and HbA1c levels prior to starting and at regular intervals during treatment. Withhold, reduce dose, or permanently discontinue REVTORPYK based on severity.

Embryo-Fetal Toxicity: Based on its mechanism of action, REVTORPYK can cause fetal harm when administered to a pregnant woman. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with REVTORPYK and for 2 weeks after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment and for 2 weeks after the last dose.

Advise women not to breastfeed during treatment with REVTORPYK and for 2 weeks after the last dose. When REVTORPYK is used in combination, advise patients to use effective contraception during treatment and for the longest post-treatment duration recommended in the Prescribing Information of any of the individual products. Verify the pregnancy status of females of reproductive potential prior to initiating treatment.

ADVERSE REACTIONS

REVTORPYK in Combination with Fulvestrant and Palbociclib: The most common (≥20%) adverse reactions, including laboratory abnormalities when given in combination with fulvestrant and palbociclib were decreased white blood cells, decreased neutrophils, decreased hemoglobin, decreased lymphocytes, stomatitis, nausea, decreased platelets, increased fasting glucose, fatigue, vomiting, rash, constipation, diarrhea, increased alanine aminotransferase (ALT), increased aspartate aminotransferase (AST), musculoskeletal pain, decreased sodium, and increased eosinophils.

REVTORPYK in Combination with Fulvestrant: The most common (≥20%) adverse reactions, including laboratory abnormalities when given in combination with fulvestrant were stomatitis, glucose increased, eosinophils increased, hemoglobin decreased, nausea, rash, ALT increased, fatigue, musculoskeletal pain, lymphocytes decreased, vomiting, AST increased, pruritus, and diarrhea.

USE IN SPECIFIC POPULATION

Lactation: Advise women not to breastfeed during treatment with REVTORPYK and for 2 weeks after the last dose. When used in combination, advise patients not to breastfeed during treatment and for the longest post-treatment duration recommended in the Prescribing Information of any of the individual products.

Infertility: Advise females and males of reproductive potential that REVTORPYK may impair fertility.

Please see full Prescribing Information, including Patient Information, for REVTORPYK.

You may report side effects related to Celcuity products to Celcuity Medical Information at 1-877-4-CELCUITY (1-877-423-5284) or to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

© 2026 Celcuity Inc. All rights reserved. REVTORPYK and its logo are trademarks of Celcuity Inc.

About Celcuity

Celcuity is a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications. The company’s first FDA-approved product is REVTORPYK (gedatolisib), a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PAM pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT or mTORC1 alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluated gedatolisib in combination with fulvestrant, with or without palbociclib, for the treatment of patients with HR+/HER2- ABC. Data from this trial is the basis for FDA approval of REVTORPYK for use in adult patients with HR+/HER2- ABC without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting. Results for the PIK3CA mutant cohort of the VIKTORIA-1 study have been released. Our Phase 3 clinical trial, VIKTORIA-2, is an ongoing trial incorporating two independent studies, Study 1 and Study 2, in two separate cohorts of patients with ABC who are treatment-naive in the advanced setting. Study 1 is evaluating gedatolisib in combination with palbociclib and fulvestrant as first-line treatment for patients with endocrine-resistant HR+/HER2- ABC. Study 2 is evaluating gedatolisib in combination with palbociclib and letrozole as first-line treatment for patients with endocrine-sensitive HR+/HER2- ABC. A Phase 1b/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration-resistant prostate cancer, is ongoing. More detailed information about Celcuity’s active clinical trials can be found at ClinicalTrials.gov. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com. Follow us on LinkedIn and X.

Forward Looking Statements

This press release contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 including statements relating to REVTORPYK and the potential therapeutic benefits of gedatolisib; the size, design and timing of the Company’s clinical trials; the Company’s interpretation of clinical trial data; the status and timing of the submission, and the FDA’s review, of the Company’s supplemental New Drug Application (“sNDA”) for REVTORPYK, and for making comparable filings with other regulatory authorities outside the U.S.; the market opportunity for REVTORPYK; the Company’s expectations regarding the timing of and its ability to commercialize REVTORPYK; the Company’s strategy, marketing and commercialization plans, including the benefits of strategic decisions regarding studies and trials; other expectations with respect to gedatolisib, including subcutaneous formulations to support potential future indications for gedatolisib regimens; the Company’s anticipated use of cash; and the strength of its balance sheet. Words such as, but not limited to, “look forward to,” “believe,” “expect,” “anticipate,” “estimate,” “intend,” “confidence,” “encouraged,” “potential,” “plan,” “targets,” “likely,” “may,” “will,” “would,” “should” and “could,” and similar expressions or words identify forward-looking statements. The forward-looking statements included in this press release are based on management’s current expectations and beliefs which are subject to a number of risks, uncertainties and factors, including that the Company’s topline clinical results are based on an ongoing analysis of efficacy and safety data and such data may change following a more comprehensive review of the data related to the clinical trial; unforeseen delays in the Company’s clinical trials or the submission, and FDA’s review of, its sNDA for REVTORPYK; the Company’s ability to obtain regulatory approval of its sNDA and maintain regulatory approvals to commercialize REVTORPYK in the U.S. and obtain regulatory approval of gedatolisib outside the U.S., and the market acceptance of REVTORPYK; the development of therapies and tools competitive with gedatolisib; and the Company’s ability to access capital upon favorable terms. In addition, all forward-looking statements are subject to other risks detailed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as such risks may be updated in its subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by these cautionary statements, and the Company undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

References:

  1. Sung H, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;10.3322/caac.21660.
  2. National Cancer Institute. Surveillance, Epidemiology and End Results Program (accessed July 2025).
    https://seer.cancer.gov/statfacts/html/breast-subtypes.html
  3. Venkatesan, A. M., et al. Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5′-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor. J Med Chem, 2010;53(6), 2636-2645. https://doi.org/10.1021/jm901830p
  4. Mallon, R., et al. Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor. Clin Cancer Res, 2011;17(10), 3193-3203. https://doi.org/10.1158/1078-0432.CCR-10-1694
  5. Rossetti, S., et al. Gedatolisib shows superior potency and efficacy versus single-node PI3K/AKT/mTOR inhibitors in breast cancer models. NPJ Breast Cancer, 2024;10(1), 40. https://doi.org/10.1038/s41523-024-00648-0

Contacts: 

For Investors: 
Brian Sullivan, bsullivan@celcuity.com
Vicky Hahne, vhahne@celcuity.com
(763) 392-0123
Jodi Sievers, jsievers@celcuity.com
(415) 494-9924

For Media:
Sam Brown LLC
Laura Morgan, lauramorgan@sambrown.com
(951) 333-9110

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/297d1d12-584a-4733-ae4f-15748ef91345

Clinical-stage agenT-797 iNKT platform selected as therapeutic cell platform for ARPA-H BoSS program aimed at taking living medicines from cryogenic storage toward room temperature

ARPA-H has committed up to $87 million across the four-year BoSS program to reduce cold-chain dependence and expand access to cell-based medicines

NEW YORK, Sept. 30, 2026 (GLOBE NEWSWIRE) — MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that its clinical-stage agenT-797 iNKT platform has been selected as a therapeutic cell system within an Advanced Research Projects Agency for Health (ARPA-H)-funded team developing technologies intended to enable living cell therapies to be stored and transported at room temperature.

The effort is part of ARPA-H’s BioStabilization Systems (BoSS) program, a four-year initiative pursuing what the agency describes as a “200-degree leap” from cryogenic storage near -196°C toward room-temperature storage near 21°C. ARPA-H has committed up to $87 million across the BoSS program to develop technologies designed to reduce dependence on cold-chain infrastructure and expand the reach of advanced biologic medicines.

MiNK is a member of the Reversible Ambient Biostabilization (RAB) team led by The Charles Stark Draper Laboratory, Inc. (“Draper”), with participation from Likarda, CPSI Biotech, OFC Life Sciences, Case BioSciences, the University of Colorado Boulder, and Fresenius Kabi. The team will use artificial intelligence (AI)-assisted design of experiments to optimize formulation, quiescence induction parameters, hydrogel composition, and recovery media. They will use freeze-assisted droplet drying to achieve a stable product.

“Cold-chain logistics remain one of the most significant barriers to scaling access to allogeneic cell therapies,” said Jennifer Buell, Ph.D., President and Chief Executive Officer of MiNK Therapeutics. “In our randomized Phase 2 trial in acute lung injury, we have already delivered agenT-797 to mechanically ventilated patients within days of regulatory authorization, even in an active conflict zone. Removing the cold chain could take that deployability to a new level: a living immune therapy stocked like a conventional drug and administered wherever critically ill patients present, including remote, resource-limited, and austere settings.”

As a core member of the RAB team, MiNK will bring its clinical-stage allogeneic iNKT platform, proprietary cGMP manufacturing infrastructure, cell-therapy development expertise, and clinically relevant production requirements to the development and evaluation of room-temperature stabilization technologies.

“iNKT cells are a rigorous benchmark for stabilization because their value lies in rapid, coordinated function: they activate within hours and orchestrate both innate and adaptive immunity, so any approach must preserve that full functional program, not just viability,” said Nils Rudqvist, Ph.D., Senior Director, Research at MiNK Therapeutics. “And because iNKT cells do not require human leukocyte antigen (HLA) matching, one manufacturing run can supply many patients. Pairing that scalability with room-temperature stability could take cell therapy beyond the specialized centers equipped for cryopreserved products and bring it to community hospitals and patients worldwide.”

For MiNK, the collaboration advances a broader strategy of developing deployable living medicines: allogeneic immune therapies designed not only for scalable manufacturing but ultimately for practical distribution and administration wherever there are patient needs.

About the ARPA-H BoSS Program

The Advanced Research Projects Agency for Health’s (ARPA-H) BioStabilization Systems (BoSS) program aims to develop technologies that enable cell therapies and other biologic medicines to be produced, stored, and transported at room temperature. If successful, the program has potential to eliminate the need for deep-freeze “cold chain” infrastructure that biologics rely on today. Drawing on approaches inspired by nature and materials science, BoSS seeks to make advanced medicines more affordable, resilient, and accessible to patients across the country, including remote and resource-limited communities. Additional information is available at arpa-h.gov/explore-funding/programs/boss.

About MiNK Therapeutics

MiNK Therapeutics, Inc. (NASDAQ: INKT) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies for cancer and other immune-mediated diseases. Its lead program, agenT-797, is an off-the-shelf, cryopreserved iNKT cell therapy in clinical development for solid tumors, graft-versus-host disease (GvHD), and severe pulmonary immune failure. MiNK’s pipeline also includes TCR-based and neoantigen-directed iNKT programs designed for tissue-specific immune activation, supported by a scalable manufacturing platform intended to make immune reconstitution therapies more durable, accessible, and globally deployable.

About agenT-797

agenT-797 is an allogeneic invariant natural killer T (iNKT) cell therapy that harnesses the dual power of innate and adaptive immunity. iNKTs function as “master regulators,” combining the cytotoxic capabilities of NK cells with T-cell–like antigen recognition and memory. This unique biology enables a robust, pathogen-agnostic immune response that can be directed against hard-to-treat tumors. Manufactured by MiNK Therapeutics in Lexington, MA, agenT-797 is a scalable, off-the-shelf product designed to provide accessible, transformative treatment options. In clinical trials, agenT-797 can bolster peripheral memory T-cell activation, enhance tumor infiltration, and potentially improve outcomes for patients with solid cancers (Cytryn et al. AACR IO 2024, Oncogene. 2024) and combat inflammation in critically ill patients with severe respiratory pathology (Nature Communications. 2024).

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws, including statements regarding the goals, timelines, and potential outcomes of the ARPA-H BoSS program, the potential benefits of biostabilization technology for agenT-797 and MiNK’s broader iNKT platform, and MiNK’s role within the RAB team. These statements are subject to risks and uncertainties, including those described under “Risk Factors” in MiNK’s most recent SEC filings, and actual results may differ materially. MiNK undertakes no obligation to update or revise these statements except as required by law.

Investor Contact
investor@minktherapeutics.com | 917-362-1370

Addressing data requirements for large model inference and AI agents to expand opportunities for all-flash server sales and technical services revenue

NEW YORK, Sept. 30, 2026 (GLOBE NEWSWIRE) — AGM Group Holdings Inc. (NASDAQ: AGMH, “AGM Group” or the “Company”) today outlined its business development plans for AI inference and AI agent applications. Building on its previously disclosed storage chip procurement plans and the commencement of mass production and deliveries of all-flash servers, the Company intends to advance product adaptation for specific applications, customer validation and expanded product deliveries to expand revenue opportunities from AI infrastructure hardware sales and technical services.

On February 5, 2026, the Company announced a strategic procurement initiative for enterprise-grade NAND flash memory and associated controller chips to support the development of its AI all-flash storage servers. On September 3, 2026, it disclosed that mass production and deliveries of all-flash servers had commenced. The current business priorities focus on further applying these supply chain and systems engineering capabilities to enterprise AI deployment scenarios.

Focusing on Data Infrastructure for AI Inference and Agent Applications

As enterprises deploy large models for knowledge retrieval, business analytics and AI agent applications, activities such as model loading, access to enterprise knowledge bases and the recording of application activity create differing requirements for data access speed, reliability and storage costs. The Company believes that providing validated storage and server solutions for these scenarios represents a business opportunity in the AI infrastructure market.

AGM intends to evaluate all-flash server configurations and software adaptations for these scenarios, with a focus on validating concurrent data access, stability during continuous operation and deployment costs. These optimizations are intended to help customers organize and access the data required by AI applications more effectively. Specific performance characteristics and suitability for particular use cases will be subject to actual testing and customer validation.

Extending from Storage Chip Selection to Server System Delivery

The Company intends to advance the coordinated selection and integration of enterprise-grade NAND flash memory, storage controllers and server architectures. Together with firmware, storage management software and thermal design, these components are intended to support product configurations for different AI application requirements. Chip supply stability, system compatibility and per-unit delivery costs will be priorities for subsequent procurement and product optimization.

AGM’s hardware engineering experience in ASIC design and specialized computing equipment provides a foundation for evaluating chip and system co-design. At this stage, the chip-related work proposed for its AI business primarily involves the selection, procurement, adaptation and system integration of storage components.

Expanding Revenue Opportunities through Product Deliveries and Technical Services

The Company intends to pursue technical discussions, product validation and commercial negotiations based on the deployment requirements of enterprise customers and computing service providers, and to schedule production and deliveries against confirmed orders. It aims to gradually expand its AI hardware business through sales of complete servers and associated systems.

Beyond hardware deliveries, AGM intends to evaluate the integration of deployment support, performance tuning and ongoing technical support into customer solutions, seeking follow-on service opportunities after equipment sales. Pricing arrangements and financial contributions from these services will depend on customer requirements and final contract terms.

As customers expand their AI deployments, additional capacity, system upgrades and maintenance support may increase each customer’s purchasing requirements over the equipment lifecycle. The Company will focus on order conversion, actual deliveries, repeat purchases, project gross profit and cash collections to assess the quality of business growth. Revenue contributions will depend on actual contract performance and recognition under applicable accounting standards.

Management Commentary

Dr. Bo Zhu, Chief Executive Officer of AGM Group Holdings Inc., commented:

“As AI moves from model development into enterprise applications, customers are paying closer attention to deployment costs, data access efficiency and the operational stability of the overall infrastructure. We aim to apply AGM’s hardware engineering experience to these specific needs and provide customers with practical solutions that span storage chip selection, system design and product delivery.

“Our next priorities are customer validation, conversion of opportunities into confirmed orders and delivery execution. As server sales and related services develop, we aim to increase the revenue contribution from our AI business and provide investors with greater visibility into our business direction and growth potential through verifiable commercial progress.”

As projects progress, the Company intends to provide timely updates on validated product configurations and application testing results, customer collaborations and orders that can be disclosed, as well as deliveries and related revenue developments. These business plans do not constitute quantitative revenue or profit guidance.

About AGM Group

AGM Group Holdings Inc. (NASDAQ: AGMH) is a technology company engaged in high-performance hardware and computing equipment. Its business encompasses ASIC design, specialized computing equipment, and AI storage and server solutions. For more information, please visit https://agmhgroup.com/.

Forward Looking Statements

This announcement contains forward-looking statements, including statements regarding AI inference and AI agent applications, chip procurement and system integration, product adaptation, customer validation, order conversion, deliveries at scale, service models and future revenue contributions. These statements are based on current expectations and involve known and unknown risks and uncertainties.

Actual results may differ materially due to factors including the progress of technology and product validation, chip supply and pricing, funding and working capital requirements, customer purchasing decisions, market competition, production costs, delivery and collection performance, applicable laws and regulations, and other risks disclosed in the Company’s filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statements, except as required by law.

Investor Relations Contact

AGM Group Holdings Inc.
Email: ir@agmhgroup.com
Website: https://agmhgroup.com/

Addressing data requirements for large model inference and AI agents to expand opportunities for all-flash server sales and technical services revenue

NEW YORK, Sept. 30, 2026 (GLOBE NEWSWIRE) — AGM Group Holdings Inc. (NASDAQ: AGMH, “AGM Group” or the “Company”) today outlined its business development plans for AI inference and AI agent applications. Building on its previously disclosed storage chip procurement plans and the commencement of mass production and deliveries of all-flash servers, the Company intends to advance product adaptation for specific applications, customer validation and expanded product deliveries to expand revenue opportunities from AI infrastructure hardware sales and technical services.

On February 5, 2026, the Company announced a strategic procurement initiative for enterprise-grade NAND flash memory and associated controller chips to support the development of its AI all-flash storage servers. On September 3, 2026, it disclosed that mass production and deliveries of all-flash servers had commenced. The current business priorities focus on further applying these supply chain and systems engineering capabilities to enterprise AI deployment scenarios.

Focusing on Data Infrastructure for AI Inference and Agent Applications

As enterprises deploy large models for knowledge retrieval, business analytics and AI agent applications, activities such as model loading, access to enterprise knowledge bases and the recording of application activity create differing requirements for data access speed, reliability and storage costs. The Company believes that providing validated storage and server solutions for these scenarios represents a business opportunity in the AI infrastructure market.

AGM intends to evaluate all-flash server configurations and software adaptations for these scenarios, with a focus on validating concurrent data access, stability during continuous operation and deployment costs. These optimizations are intended to help customers organize and access the data required by AI applications more effectively. Specific performance characteristics and suitability for particular use cases will be subject to actual testing and customer validation.

Extending from Storage Chip Selection to Server System Delivery

The Company intends to advance the coordinated selection and integration of enterprise-grade NAND flash memory, storage controllers and server architectures. Together with firmware, storage management software and thermal design, these components are intended to support product configurations for different AI application requirements. Chip supply stability, system compatibility and per-unit delivery costs will be priorities for subsequent procurement and product optimization.

AGM’s hardware engineering experience in ASIC design and specialized computing equipment provides a foundation for evaluating chip and system co-design. At this stage, the chip-related work proposed for its AI business primarily involves the selection, procurement, adaptation and system integration of storage components.

Expanding Revenue Opportunities through Product Deliveries and Technical Services

The Company intends to pursue technical discussions, product validation and commercial negotiations based on the deployment requirements of enterprise customers and computing service providers, and to schedule production and deliveries against confirmed orders. It aims to gradually expand its AI hardware business through sales of complete servers and associated systems.

Beyond hardware deliveries, AGM intends to evaluate the integration of deployment support, performance tuning and ongoing technical support into customer solutions, seeking follow-on service opportunities after equipment sales. Pricing arrangements and financial contributions from these services will depend on customer requirements and final contract terms.

As customers expand their AI deployments, additional capacity, system upgrades and maintenance support may increase each customer’s purchasing requirements over the equipment lifecycle. The Company will focus on order conversion, actual deliveries, repeat purchases, project gross profit and cash collections to assess the quality of business growth. Revenue contributions will depend on actual contract performance and recognition under applicable accounting standards.

Management Commentary

Dr. Bo Zhu, Chief Executive Officer of AGM Group Holdings Inc., commented:

“As AI moves from model development into enterprise applications, customers are paying closer attention to deployment costs, data access efficiency and the operational stability of the overall infrastructure. We aim to apply AGM’s hardware engineering experience to these specific needs and provide customers with practical solutions that span storage chip selection, system design and product delivery.

“Our next priorities are customer validation, conversion of opportunities into confirmed orders and delivery execution. As server sales and related services develop, we aim to increase the revenue contribution from our AI business and provide investors with greater visibility into our business direction and growth potential through verifiable commercial progress.”

As projects progress, the Company intends to provide timely updates on validated product configurations and application testing results, customer collaborations and orders that can be disclosed, as well as deliveries and related revenue developments. These business plans do not constitute quantitative revenue or profit guidance.

About AGM Group

AGM Group Holdings Inc. (NASDAQ: AGMH) is a technology company engaged in high-performance hardware and computing equipment. Its business encompasses ASIC design, specialized computing equipment, and AI storage and server solutions. For more information, please visit https://agmhgroup.com/.

Forward Looking Statements

This announcement contains forward-looking statements, including statements regarding AI inference and AI agent applications, chip procurement and system integration, product adaptation, customer validation, order conversion, deliveries at scale, service models and future revenue contributions. These statements are based on current expectations and involve known and unknown risks and uncertainties.

Actual results may differ materially due to factors including the progress of technology and product validation, chip supply and pricing, funding and working capital requirements, customer purchasing decisions, market competition, production costs, delivery and collection performance, applicable laws and regulations, and other risks disclosed in the Company’s filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statements, except as required by law.

Investor Relations Contact

AGM Group Holdings Inc.
Email: ir@agmhgroup.com
Website: https://agmhgroup.com/

TORONTO, Sept. 30, 2026 (GLOBE NEWSWIRE) — Centerra Gold Inc. (“Centerra” or the “Company”) (TSX: CG) (NYSE: CGAU) will release its third quarter 2026 operating and financial results after the market closes on Thursday October 29, 2026. The Company will host a conference call and webcast to discuss the results on Friday October 30, 2026, at 9:00 a.m. Eastern Time. Details for the conference call and webcast are included below.

Webcast

  • Participants can access the webcast at the following webcast link.
  • An archive of the webcast will be available until the end of day on January 30, 2027.

Conference Call

  • Participants can register for the conference call at the following registration link. Upon registration, you will receive the dial-in details and a unique PIN to access the call. This process will bypass the live operator and avoid the queue. Registration will remain open until the end of the live conference call.
  • Participants who prefer to dial in and speak with a live operator can access the call by dialing 1-833-821-3536 or 647-846-2628. It is recommended that you call 10 minutes before the scheduled start time.
  • After the call, an audio recording will be made available via telephone for one month, until the end of day November 30, 2026. The recording can be accessed by dialing 1-855-669-9658 or 412-317-0088 and using the access code 7065248. In addition, the webcast will be archived on Centerra’s website at www.centerragold.com/investor-relations/events-and-presentations/
  • Presentation slides will be available on Centerra’s website at www.centerragold.com.

About Centerra Gold

Centerra Gold Inc. is a Canadian-based gold and copper producer and developer headquartered in Toronto, Ontario. The Company operates two mines: the Mount Milligan Mine, a long-life gold-copper asset in British Columbia, Canada, and the Öksüt Mine, a gold asset in Türkiye. Centerra has a self-funded organic growth pipeline in North America, including the Kemess gold-copper Project in British Columbia, Canada, and the Goldfield gold Project in Nevada, United States. The Company also owns and operates US Moly, a vertically integrated molybdenum business in the United States comprising the Thompson Creek Mine in Idaho and the Langeloth Metallurgical Facility in Pennsylvania. Centerra’s shares trade on the Toronto Stock Exchange (TSX: CG) and on the New York Stock Exchange (NYSE: CGAU).

For more information:

Lisa Wilkinson
Vice President, Investor Relations & Corporate Communications
(416) 204-3780
Lisa.Wilkinson@centerragold.com

Additional information on Centerra is available on the Company’s website at www.centerragold.com, on SEDAR+ at www.sedarplus.ca and EDGAR at www.sec.gov/edgar.

TORONTO, Sept. 30, 2026 (GLOBE NEWSWIRE) — Centerra Gold Inc. (“Centerra” or the “Company”) (TSX: CG) (NYSE: CGAU) will release its third quarter 2026 operating and financial results after the market closes on Thursday October 29, 2026. The Company will host a conference call and webcast to discuss the results on Friday October 30, 2026, at 9:00 a.m. Eastern Time. Details for the conference call and webcast are included below.

Webcast

  • Participants can access the webcast at the following webcast link.
  • An archive of the webcast will be available until the end of day on January 30, 2027.

Conference Call

  • Participants can register for the conference call at the following registration link. Upon registration, you will receive the dial-in details and a unique PIN to access the call. This process will bypass the live operator and avoid the queue. Registration will remain open until the end of the live conference call.
  • Participants who prefer to dial in and speak with a live operator can access the call by dialing 1-833-821-3536 or 647-846-2628. It is recommended that you call 10 minutes before the scheduled start time.
  • After the call, an audio recording will be made available via telephone for one month, until the end of day November 30, 2026. The recording can be accessed by dialing 1-855-669-9658 or 412-317-0088 and using the access code 7065248. In addition, the webcast will be archived on Centerra’s website at www.centerragold.com/investor-relations/events-and-presentations/
  • Presentation slides will be available on Centerra’s website at www.centerragold.com.

About Centerra Gold

Centerra Gold Inc. is a Canadian-based gold and copper producer and developer headquartered in Toronto, Ontario. The Company operates two mines: the Mount Milligan Mine, a long-life gold-copper asset in British Columbia, Canada, and the Öksüt Mine, a gold asset in Türkiye. Centerra has a self-funded organic growth pipeline in North America, including the Kemess gold-copper Project in British Columbia, Canada, and the Goldfield gold Project in Nevada, United States. The Company also owns and operates US Moly, a vertically integrated molybdenum business in the United States comprising the Thompson Creek Mine in Idaho and the Langeloth Metallurgical Facility in Pennsylvania. Centerra’s shares trade on the Toronto Stock Exchange (TSX: CG) and on the New York Stock Exchange (NYSE: CGAU).

For more information:

Lisa Wilkinson
Vice President, Investor Relations & Corporate Communications
(416) 204-3780
Lisa.Wilkinson@centerragold.com

Additional information on Centerra is available on the Company’s website at www.centerragold.com, on SEDAR+ at www.sedarplus.ca and EDGAR at www.sec.gov/edgar.

DLR Kredit A/S
Andre oplysningsforpligtelser offentliggjort efter børsens regler

DLR Kredit har fastsat kuponrenter for perioden 2. oktober 2026 til 4. januar 2027
på følgende Senior Non-Preferred Notes (SEK):

ISIN Navn Referencerente NyRente
DK0030551320 SNP July 2029 STIBOR3M 3,907%

Spørgsmål kan rettes til Fonds og Funding, fonds@dlr.dk eller pr. tlf 33 42 07 38

Med venlig hilsen
DLR Kredit

Attachment

MIAMI, Sept. 30, 2026 (GLOBE NEWSWIRE) — NCL Corporation Ltd. (“NCLC”), a subsidiary of Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) (“NCLH”), announced today that it is proposing to sell $750.0 million aggregate principal amount of its senior notes due 2031 (the “Notes”) in a private offering (the “Offering”) that is exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”).

NCLC intends to use the net proceeds from the Offering, together with cash on hand, (i) to redeem all of the outstanding 6.125% Senior Notes due 2028 issued by NCL Finance, Ltd., a subsidiary of NCLC (the “2028 Notes”), (ii) to repay approximately $176.3 million of outstanding borrowings under NCLC’s existing senior secured revolving loan facility and (iii) to prepay approximately $42.2 million of outstanding borrowings under our export-credit backed financing facilities, in each case, together with any accrued and unpaid interest thereon, and to pay any related transaction premiums, fees and expenses. The redemption of the 2028 Notes will be conditioned upon the consummation of the Offering.

The Notes are being offered only to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act, and outside the United States, only to non-U.S. investors pursuant to Regulation S under the Securities Act. The Notes will not be registered under the Securities Act or the securities laws of any state and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state laws.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful. This press release also shall not constitute an offer to purchase, a solicitation of an offer to sell, or a notice of redemption with respect to the 2028 Notes.

About Norwegian Cruise Line Holdings Ltd.

Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) is a leading global cruise company which operates Norwegian Cruise Line®, Oceania Cruises® and Regent Seven Seas Cruises®. NCLH has a combined fleet of 33 ships and approximately 72,000 berths, excluding two ships under long-term charter to third parties, and offers itineraries to nearly 700 destinations worldwide. NCLH expects to add 16 additional ships across its three brands through 2037, which will add approximately 43,000 berths to its fleet.

Cautionary Statement Concerning Forward-Looking Statements

Some of the statements, estimates or projections contained in this press release are “forward-looking statements” within the meaning of the U.S. federal securities laws intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release, including statements regarding the Offering and the use of proceeds therefrom, may be forward-looking statements. Many, but not all, of these statements can be found by looking for words like “expect,” “anticipate,” “goal,” “project,” “plan,” “believe,” “seek,” “will,” “may,” “forecast,” “estimate,” “intend,” “future” and similar words. Forward-looking statements do not guarantee future performance and may involve risks, uncertainties and other factors which could cause our actual results, performance or achievements to differ materially from the future results, performance or achievements expressed or implied in those forward-looking statements. For a discussion of these risks, uncertainties and other factors, please refer to the factors set forth under the sections entitled “Risk Factors” and “Cautionary Statement Concerning Forward-Looking Statements” in our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and subsequent filings with the Securities and Exchange Commission. These factors are not exhaustive and new risks emerge from time to time. There may be additional risks that we consider immaterial or which are unknown. Such forward-looking statements are based on our current beliefs, assumptions, expectations, estimates and projections regarding our present and future business strategies and the environment in which we expect to operate in the future. These forward-looking statements speak only as of the date made. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement to reflect any change in our expectations with regard thereto or any change of events, conditions or circumstances on which any such statement was based, except as required by law.

Investor Relations & Media Contact

Sarah Inmon
(786) 812-3233
InvestorRelations@nclcorp.com

MIAMI, Sept. 30, 2026 (GLOBE NEWSWIRE) — NCL Corporation Ltd. (“NCLC”), a subsidiary of Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) (“NCLH”), announced today that it is proposing to sell $750.0 million aggregate principal amount of its senior notes due 2031 (the “Notes”) in a private offering (the “Offering”) that is exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”).

NCLC intends to use the net proceeds from the Offering, together with cash on hand, (i) to redeem all of the outstanding 6.125% Senior Notes due 2028 issued by NCL Finance, Ltd., a subsidiary of NCLC (the “2028 Notes”), (ii) to repay approximately $176.3 million of outstanding borrowings under NCLC’s existing senior secured revolving loan facility and (iii) to prepay approximately $42.2 million of outstanding borrowings under our export-credit backed financing facilities, in each case, together with any accrued and unpaid interest thereon, and to pay any related transaction premiums, fees and expenses. The redemption of the 2028 Notes will be conditioned upon the consummation of the Offering.

The Notes are being offered only to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act, and outside the United States, only to non-U.S. investors pursuant to Regulation S under the Securities Act. The Notes will not be registered under the Securities Act or the securities laws of any state and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state laws.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful. This press release also shall not constitute an offer to purchase, a solicitation of an offer to sell, or a notice of redemption with respect to the 2028 Notes.

About Norwegian Cruise Line Holdings Ltd.

Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) is a leading global cruise company which operates Norwegian Cruise Line®, Oceania Cruises® and Regent Seven Seas Cruises®. NCLH has a combined fleet of 33 ships and approximately 72,000 berths, excluding two ships under long-term charter to third parties, and offers itineraries to nearly 700 destinations worldwide. NCLH expects to add 16 additional ships across its three brands through 2037, which will add approximately 43,000 berths to its fleet.

Cautionary Statement Concerning Forward-Looking Statements

Some of the statements, estimates or projections contained in this press release are “forward-looking statements” within the meaning of the U.S. federal securities laws intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release, including statements regarding the Offering and the use of proceeds therefrom, may be forward-looking statements. Many, but not all, of these statements can be found by looking for words like “expect,” “anticipate,” “goal,” “project,” “plan,” “believe,” “seek,” “will,” “may,” “forecast,” “estimate,” “intend,” “future” and similar words. Forward-looking statements do not guarantee future performance and may involve risks, uncertainties and other factors which could cause our actual results, performance or achievements to differ materially from the future results, performance or achievements expressed or implied in those forward-looking statements. For a discussion of these risks, uncertainties and other factors, please refer to the factors set forth under the sections entitled “Risk Factors” and “Cautionary Statement Concerning Forward-Looking Statements” in our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and subsequent filings with the Securities and Exchange Commission. These factors are not exhaustive and new risks emerge from time to time. There may be additional risks that we consider immaterial or which are unknown. Such forward-looking statements are based on our current beliefs, assumptions, expectations, estimates and projections regarding our present and future business strategies and the environment in which we expect to operate in the future. These forward-looking statements speak only as of the date made. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement to reflect any change in our expectations with regard thereto or any change of events, conditions or circumstances on which any such statement was based, except as required by law.

Investor Relations & Media Contact

Sarah Inmon
(786) 812-3233
InvestorRelations@nclcorp.com

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.